Becton, Dickinson(US:BDX) 仪器信息网·2025-08-09 04:04Core Viewpoint - The localization of the BD FACS-Lyric flow cytometer marks a significant milestone for BD Medical in its 45-year journey alongside the development of flow cytometry technology in China, transitioning from technology leadership to ecosystem building [2][5]. Group 1: Localization Strategy - The first domestically produced BD FACS-Lyric flow cytometer officially began mass production on August 8, 2025, representing a key achievement in BD Medical's strategy of "rooting in China and serving China" [3]. - The localization project is seen as a strategic upgrade following the localization of consumables, aiming to establish a comprehensive local production system that facilitates the introduction of world-class flow cytometry products and technologies in China [5]. Group 2: Industry Collaboration - BD Medical's localization strategy emphasizes deep collaboration within the industry chain, integrating international flow cytometry technology with local practical needs through technical guidance and shared experiences [6]. - This collaboration enhances the technical capabilities of local teams and activates the synergy across the industry chain, from reagent production to equipment maintenance and technical services, thereby laying a solid foundation for improving local innovation capabilities [6]. Group 3: Service System - The core of the localization strategy is the establishment of a comprehensive local service system focused on customization and responsiveness to meet the demands of the Chinese market [7]. - BD Medical provides tailored local services for the BD FACS-Lyric flow cytometer, including precise instrument installation, scenario-based operational training, and professional application support, aimed at maximizing equipment performance and enhancing clinical testing efficiency and research innovation [7].